Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

September 12, 2005

Last Updated Date

November 6, 2008

Start Date ^†

Current Primary Outcome Measures ^†

Afebrile at 24 hours and no endometritis

Original Primary Outcome Measures ^†

Same as current

Change History

Complete list of historical versions of study NCT00185991 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Neonatal outcomes

Original Secondary Outcome Measures ^†

Same as current

Descriptive Information

Brief Title ^†

Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis

Official Title ^†

Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis

Brief Summary

To compare once daily versus 8 hour dosing of gentamicin for the treatment of chorioamnionitis.

Detailed Description

Study Phase

Study Type ^†

Interventional

Study Design ^†

Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Efficacy Study

Condition ^†

Chorioamnionitis

Intervention ^†

Drug: gentamicin

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Active, not recruiting

Enrollment ^†

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria::

clinical diagnosis of chorioamnionitis
 Exclusion Criteria:- maternal renal disease, intrauterine fetal death, allergy to gentamicin

Gender

Female

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00185991

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Stanford University

Collaborators ^††

Investigators ^†

Principal Investigator:

Yasser Yehia El-Sayed

Stanford University

Information Provided By

Stanford University

Verification Date

November 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.